Document:

EX-10.14

 Exhibit 10.14 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 MANAGEMENT
SERVICES AGREEMENT 
 THIS MANAGEMENT SERVICES AGREEMENT (this
“Agreement”), effective as of October 1, 2014 (the “Effective Date”), is by and between KURA ONCOLOGY, INC., a Delaware corporation
(“Kura”), and ARAXES PHARMA LLC, a Delaware limited liability company (the “Company”). 

WHEREAS, the Company desires to engage Kura to provide the Company various services and make available to
the Company certain resources of Kura on the terms set forth herein. 
 NOW, THEREFORE,
in consideration of the above promises and for other good and valid consideration, the receipt and adequacy of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows: 

ARTICLE 1 

DEFINED TERMS 

1.1 “Company Confidential Information” shall mean (a) the Company Work Product and (b) any and all other data,
information, technology, samples and specimens of the Company or its products, product concepts, technologies, businesses, financial, marketing, clinical or regulatory affairs, manufacturing processes and procedures, or those of any other third
party, whether written, graphic or oral, and whether or not furnished to or obtained by Kura, either directly or indirectly, during the course of performing Services hereunder; but excluding, in any event, the Methodology Information and Kura Work
Product. Kura shall be considered the receiving party with respect to all Company Confidential Information. 
 1.2 “Company
Intellectual Property” shall have the meaning provided in Section 2.5(a). 
 1.3 “Company Work Product” shall
mean any and all results (including data) and products (interim and/or final) of the Services performed by Kura or its subcontractors, consultants or agents, whether tangible or intangible, including, without limitation, each and every invention
(whether or not patentable), discovery, design, drawing, protocol, process, technique, formula, trade secret, device, compound, substance, material, pharmaceutical, method, software program (including without limitation, object code, source code,
flow charts, algorithms and related documentation), listing, routine, manual and specification, whether or not patentable or copyrightable, that are made, developed, perfected, designed, conceived or first reduced to practice by Kura, (or its
subcontractors, consultants or agents), either solely or jointly with others, in the course of the Services. Notwithstanding the foregoing, Company Work Product shall specifically exclude Methodology Information. 

  
 1 

 1.4 “Confidential Information” shall mean the Kura Confidential Information or
the Company’s Confidential Information, as applicable. 
 1.5 “Materials” shall mean any chemical or biological
materials provided by the Company to Kura for use in the Services or procured by Kura specifically for use in the Services. For clarity, in the event a sequence or structure is provided in lieu of physical quantities, the term “Materials”
will be deemed to include such sequences or structures and the physical material derived therefrom. 
 1.6 “Methodology
Information” shall mean any methods or processes used or developed by or for Kura in or for the provision of Services, or in any documentation, records, raw data, materials (other than Materials), specimens, work product, concepts,
information, inventions, improvements, designs, programs, formulas, know-how, or writings related thereto, except those methods and/or processes, if any, disclosed or provided by the Company to Kura as specified in writing and agreed to by Kura.

 1.7 “Services” shall have the meaning provided in Section 2.1. 

1.8 “Term” shall have the meaning provided in Section 2.6. 

1.9 “Kura Confidential Information” shall mean (a) the Kura Work Product and (b) all data, information, technology,
samples and specimens of Kura or any other person or entity with which Kura has a commercial relationship (other than the Company) or their respective products, technologies, businesses, financial, marketing, clinical or regulatory affairs,
manufacturing processes and procedures, or those of any other third party from whom Kura receives information on a confidential basis, whether written, graphic or oral, furnished to or obtained by the Company, either directly or indirectly, during
the course of receiving Services hereunder, including, without limitation, Methodology Information, but excluding the Company’s Work Product. The Company shall be considered the receiving party with respect to all Kura Confidential Information.

 1.10 “Kura Intellectual Property” shall have the meaning provided in Section 2.5(a). 

1.11 “Kura Key Team” shall mean the individuals as specified on Exhibit A hereto as amended from time to time and such
other individuals as may be agreed to between Kura and the Company from time to time. 
 1.12 “Kura Work Product” shall
mean any and all results (including data) and products (interim and/or final) of any activities or services performed by Kura on behalf of itself or any third party, other than in the course of performing the Services, whether tangible or
intangible, including, without limitation, each and every invention (whether or not patentable), discovery, design, drawing, protocol, process, technique, formula, trade secret, device, compound, substance, material, pharmaceutical, method, software
program (including without limitation, object code, source code, flow charts, algorithms and related documentation), listing, routine, manual and specification, whether or not patentable or copyrightable, and that are made, developed, perfected,
designed, conceived or first reduced to practice by Kura, either solely or jointly with others, whether before, during or after the Term, including, without limitation, the Methodology Information. 

  
 2 

 ARTICLE 2 

SERVICES 

2.1 Services. Subject to the terms of this Agreement, for the Term determined pursuant to Section 2.6(a) hereof, Kura shall
provide or cause to be provided to the Company such services, in the nature of those described on Exhibit A, as may reasonably be requested by the Company and reasonably approved by Kura from time to time following the date hereof (the
“Services”). 
 2.2 Charges and Payment. As compensation for its services hereunder, Kura shall be entitled
to receive from the Company, and the Company is obligated to pay fees to Kura, for the provision of the Services. The Company shall pay Kura for the Services in accordance with the provisions of Exhibit B attached hereto. 

2.3 General Obligations; Standard of Care. 

(a) Performance Requirements. Kura shall use commercially reasonable efforts to provide Services subject to the terms of this Agreement
and in accordance with its policies, procedures and practices then in effect, and shall exercise substantially the same care and skill as it exercises in performing similar activities to the services for itself. 

(b) Changes. The parties acknowledge that Kura may make changes from time to time in the manner of performing the Services. Such
changes shall be made in consultation with the Company. 
 (c) Compliance. Kura agrees to perform the Services in accordance with the
terms and conditions contained in this Agreement and in compliance with all applicable federal, state and local laws and regulations including without limitation, the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et.
seq.) as amended (“FCPA”). In furtherance of the foregoing, Kura shall conduct its activities hereunder in accordance with the guidelines set forth in Exhibit C (Compliance with Laws and the FCPA). 

(d) Communication. On a regular basis during the Term, the parties shall conduct meetings, either in person or by telephone or video
conference, to discuss the progress and results of the Services. 
 (e) Services by Kura Key Team. It is the present intention of
Kura that substantially all of the Services will be provided and/or overseen by members of the Kura Key Team, as agreed from time to time. 

(f) Subcontracting. Kura may subcontract Services to third parties provided that Kura will ensure that it enters into an agreement with
each subcontractor that, at a minimum, provides for ownership and allocation of intellectual property rights and for obligations of confidentiality of information that are consistent with the intent and terms of this Agreement. Kura will remain
liable to Company for the performance of any of its obligations hereunder that it delegates to a subcontractor. 

  
 3 

 2.4 Confidentiality. 

(a) Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the parties, the
parties agree that, during the Term of this Agreement and thereafter, the receiving party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement
any Confidential Information of the other party. Each party may use the other party’s Confidential Information only to the extent required to accomplish the purposes of this Agreement, consistent with any restrictions on the use of Confidential
Information received from a third party and communicated by the party disclosing such Confidential Information (“Third Party Restrictions”). To the extent that any Third Party Restrictions exceed the restrictions on the use
of Confidential Information set forth in this Agreement, the parties each hereby agree to be bound by such Third Party Restrictions. The parties agree and acknowledge that certain Confidential Information may be required for submission to the U.S.
Food and Drug Administration and/or federal or state regulatory bodies. The parties acknowledge and agree that such submissions, to the extent required by applicable law, shall not constitute a violation of the terms of this Agreement if permitted
under any applicable agreement with a third party from whom the disclosing party obtained the Confidential Information. Each party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own
(but in no event less than reasonable care) to ensure that its employees, agents, consultants and other representatives do not disclose or make any unauthorized use of such Confidential Information. Each party will promptly notify the other upon
discovery of any unauthorized use or disclosure of such Confidential Information. 
 (b) Limitations. Confidential Information shall
not include any information that the receiving party can prove by competent evidence: (i) was already known to the receiving party without any obligations of confidentiality prior to receipt from the other party; (ii) was generally
available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; (iii) became generally available to the public or otherwise part of the public domain after its disclosure, other than through
any act or omission of the receiving party in breach of any obligation of confidentiality; (iv) was disclosed to the receiving party, other than under an obligation of confidentiality, by a third party who had no obligation not to disclose such
information to others; or (v) was independently discovered or developed by the receiving party without the use of Confidential Information; provided, however, that any combination of features or disclosures shall not be deemed to fall
within the foregoing exclusions solely because certain individual features are published or available to the general public or in the rightful possession of a party unless the combination as a whole falls within any of the above exceptions. 

(c) Authorized Disclosure. Notwithstanding Section 2.4(a), a party may disclose Confidential Information of the other party,
without violating the obligations of this Agreement, to the extent the disclosure is required by a valid order of a court or other governmental body having jurisdiction, provided that such party gives reasonable prior written notice to the other
party of such required disclosure and makes a reasonable effort to obtain, or to assist the other party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the Confidential Information so disclosed be used
only for the purposes for which the law or regulation requires, or for which the order was issued. 

  
 4 

 (d) Use of Name/Publicity. Neither party shall use the other party’s name in
connection with any publication or promotion without the other party’s written consent, except as required by federal, state or local laws, rules and regulations. Neither party shall disclose the specific content or terms of this Agreement
without the prior written consent of the other party. 
 2.5 Intellectual Property Rights 

(a) Ownership. The Company shall own all right, title and interest in and to all Materials and Company Work Product, including, without
limitation, all patent, copyright or other intellectual property rights therein, that is conceived or first reduced to practice by Kura, or its subcontractors, consultants or agents, either solely or jointly with others, in the course of performing
the Services (collectively, the “Company Intellectual Property”), and neither this Agreement, nor the provision of the Services hereunder, shall give Kura any right, title or interest in or to any Company Intellectual
Property except as provided in the following sentence. The Company hereby grants to Kura a non-exclusive, worldwide, fully-paid, royalty-free license, without the right to sublicense, under the Company Intellectual Property solely as necessary or
appropriate to perform Services under this Agreement during the Term. Kura shall retain all right, title and interest in and to any and all Methodology Information and Kura Work Product, including, without limitation, all patent, copyright or other
intellectual property rights therein (collectively, the “Kura Intellectual Property”), and neither this Agreement, nor the provision of the Services hereunder, shall give the Company any right, title or interest in or to any
Kura Intellectual Property except as provided in the following sentence. In the event that in the performance of the Services, Kura utilizes Kura Intellectual Property, Kura hereby grants to the Company a non-exclusive, worldwide, fully-paid,
royalty-free license, without the right to sublicense, under such Kura Intellectual Property solely as necessary for the Company or its affiliates or licensees (other than Kura) to develop, make, have made, use, sell, offer to sell and import
products. 
 (b) Assignment; Assistance. Kura hereby assigns all of Kura’s right, title and interest in and to any Company
Intellectual Property to the Company without royalty or any other consideration and agrees to execute all applications, assignments or other instruments reasonably requested by the Company in order for the Company to establish its ownership of such
Company Intellectual Property and to obtain whatever protection for such Company Intellectual Property, including copyright and patent rights in any and all countries designated by the Company on such Company Intellectual Property as the Company
shall determine. Kura agrees to assist the Company, or its designee, in every reasonable way (but at the Company’s expense) to secure the Company’s rights in Company Intellectual Property and any copyrights, patents or other intellectual
property rights relating to all Company Intellectual Property in any and all countries designated by the Company, including the disclosure to the Company of all pertinent information and data with respect to all Company Intellectual Property, the
execution of all applications, specifications, oaths, assignments and all other instruments that the Company may deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns
and nominees the sole and exclusive right, title and interest in and to all Company Intellectual Property. Kura also agrees that its obligation to execute or cause to be executed any such instrument or papers shall continue after the expiration or
termination of this Agreement. Kura agrees that, if the Company is unable because of Kura’s unavailability, dissolution, or otherwise, to secure Kura’s signature for the purpose of applying

  
 5 

 
for or pursuing any application for any United States or foreign patents or copyright registrations covering the Company Intellectual Property assigned to the Company herein, then, until such
time Kura becomes available it hereby designates and appoints the Company and its duly authorized officers and agents as Kura’s agent and attorney-in-fact, to act for and on Kura’s behalf to execute and file any such applications and to do
all other lawfully permitted acts only to further the prosecution and issuance of patents and copyright registrations with the same legal force and effect as if executed by Kura. 

(c) Protection of Privileged Advice Shared for Common Interest. For the avoidance of doubt, any opinions or other advice of any
qualified legal personnel (whether a patent attorney or other counsel) representing a party hereunder communicated to the other party or both parties, directly by such legal personnel or indirectly such as through a patent liaison for common
interest purposes contemplated hereunder, shall be held in strict confidence to protect the privileged nature thereof, and not disclosed to any Third Party without the prior written consent of both parties, each under the advice of its respective
legal counsel. 
 2.6 Term; Termination. 

(a) Term. This Agreement shall be in effect from the Effective Date until December 31, 2015 (the “Initial
Term”) and shall be renewed automatically thereafter for additional consecutive periods of one (1) year each (each a “Renewal Term”) unless either party gives notice to the other party of its intention to
terminate at least thirty (30) days prior to the expiration of the Initial Term or then-current Renewal Term, as applicable (the Initial Term and all Renewal Terms, collectively, the “Term”). 

(b) Election to Terminate. The Company may terminate this Agreement either with respect to all, or with respect to any one or more, of
the Services provided hereunder (including, without limitation, terminating the provision of Services by any member or members of the Kura Key Team) at any time and from time to time, for any reason or no reason, by giving written notice to Kura at
least thirty (30) days prior to the date of such termination. Kura may terminate this Agreement either with respect to all, or with respect to any one or more, of the Services provided hereunder at any time and from time to time, for any reason
or no reason, by giving written notice to the Company at least thirty (30) days prior to the date of such termination. In addition, the parties may at any time agree in writing to terminate this Agreement with respect to some or all of the
Services, effective immediately or as indicated in such writing. In the event of any termination with respect to one or more, but less than all, Services, this Agreement shall continue in full force and effect with respect to any Services not
terminated hereby. 
 (c) Payment Upon Early Termination. In the event of termination of this Agreement or any Services hereunder,
Kura shall be paid for all work completed through the date of termination in accordance with this Agreement, including reasonable and documented out-of-pocket expenses and any non-cancelable commitments
incurred by Kura in accordance with this Agreement. Kura shall refund to the Company any prepaid amounts not earned by Kura prior to the date of such termination, including as set forth in Section 2.2 hereof. 

  
 6 

 (d) Survival Upon Termination. Expiration or termination of this Agreement will not
relieve either party of any obligation accruing prior to such expiration or termination. Article 1, Sections 2.2, 2.4, 2.5, 2.6(c), 2.6(d), 3.4 and 3.5, and Articles 4 and 5 will survive expiration or termination of this Agreement. 

ARTICLE 3 

REPRESENTATIONS AND WARRANTIES; DISCLAIMER; LIMITATION
OF LIABILITY. 
 3.1 Mutual Representations and Warranties. Each party represents and warrants to
the other that: (a) it has full power and authority to enter into this Agreement and to perform its obligations hereunder; (b) this Agreement is legally binding upon it, enforceable against it in accordance with its terms, and does not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over it; and (c) such party is not under any pre-existing obligation inconsistent with the provisions of this Agreement. 

3.2 Kura Representations and Warranties. Kura hereby represents and warrants to the Company that: 

(a) the Services shall be performed by qualified personnel in a good, timely, efficient and professional manner; 

(b) Kura shall perform the Services in compliance with all applicable laws, rules and regulations, including but not limited to the
U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder. The parties acknowledge and agree that Kura does not warrant or represent that the results of the Services will be acceptable to any regulatory agency to which they are
presented nor that the Company will be able to market or otherwise exploit any Company Work Product; and 
 (c) neither Kura nor any
Kura contractors or personnel performing Services under this Agreement have been: (i) debarred, or proposed to be debarred under Section 306(a) or 306(b) of the United States Federal Food, Drug and Cosmetic Act, as amended from time to
time, and the rules, regulations and guidelines promulgated thereunder, or under 42 U.S.C. Section 1320-7; (ii) sanctioned by, suspended, debarred, excluded or otherwise ineligible to participate in any federal or state health care
program, including Medicare and Medicaid or in any federal procurement or non-procurement programs; or (iii) charged with or convicted of any felony or misdemeanor under 42 U.S.C. Section 1320a-7(a) or 42 U.S.C.
Section 1320a-7(b)(1)-(3), or otherwise proposed for exclusion. Kura will promptly inform the Company, but in no event later than four (4) Business Days, if Kura becomes aware that its or any of its subcontractors, or any employee of Kura
or any of its subcontractors, in each case performing any Services related to development activities or in support of the marketing authorizations, is not in compliance with any of the criteria set forth in this Section 3.2(c) on or after the
Effective Date. 

  
 7 

 3.3 Company Representations and Warranties. The Company hereby represents and warrants to
Kura that: 
 (a) to the extent this Agreement provides for the Company to provide Kura with any Materials, the Company has the right
to provide such Materials to Kura for use as contemplated by this Agreement; and 
 (b) to the Company’s knowledge, the use of
such Materials as contemplated by this Agreement will not infringe the intellectual property rights of any third party. 
 3.4 Disclaimer
of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. WITHOUT
LIMITING THE GENERALITY OF THE FOREGOING, AND EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, KURA MAKES NO REPRESENTATIONS OR WARRANTIES AS TO THE QUALITY, SUITABILITY OR ADEQUACY OF THE SERVICES FOR ANY PURPOSE OR USE. 

3.5 Limitation of Liability. NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR
PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT; provided, however, that this Section 3.5 shall not apply to any breaches of Section 2.4 or be construed to limit either party’s indemnification obligations under
Article 4. 
 ARTICLE 4 

INDEMNIFICATION. 

4.1 By the Company. The Company hereby agrees to save, defend, indemnify and hold harmless Kura, its affiliates (other than the
Company) and their respective officers, directors, employees, consultants and agents (each, a “Kura Party”) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and
attorneys’ fees (“Losses”), to which any Kura Party may become subject as a result of any claim, demand, action or other proceeding by any third party to the extent such Losses arise directly or indirectly out of
(a) the performance of the Services, (b) the development, manufacture, use, handling, storage, sale or other disposition of any product by the Company, or (c) the gross negligence or willful misconduct of any Company Party (as defined
below) or the breach by the Company of any warranty, representation, covenant or agreement made by the Company in this Agreement, except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any Kura
Party or the breach by Kura of any warranty, representation, covenant or agreement made by Kura in this Agreement. 
 4.2 By Kura.
Kura hereby agrees to save, defend, indemnify and hold harmless the Company, its affiliates and their respective officers, directors, employees, consultants and agents (each, a “Company Party”) from and against any and all
Losses to which any Company Party may become subject as a result of any claim, demand, action or other proceeding by any third 

  
 8 

 
party to the extent such Losses arise directly or indirectly out of the gross negligence or willful misconduct of any Kura Party or the breach by Kura of any warranty, representation, covenant or
agreement made by Kura in this Agreement, except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any Company Party or the breach by the Company of any warranty, representation, covenant or agreement
made by the Company in this Agreement. 
 4.3 Control of Defense. In the event a party seeks indemnification under Section 4.1
or Section 4.2, it shall inform the other party (the “Indemnifying Party”) of a claim as soon as reasonably practicable after it receives notice of the claim, shall permit the Indemnifying Party to assume direction and
control of the defense of the claim (including the right to settle the claim solely for monetary consideration with no admission of fault), and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. 

4.4 Liability Insurance. Each party agrees to maintain during the Term usual and customary liability, workers compensation and errors
and omissions insurance in amounts consistent with industry standards and to provide a certificate of insurance evidencing such coverage to the other party upon request. 

ARTICLE 5 

MISCELLANEOUS 

5.1 Taxes. Kura will pay any and all taxes levied on account of any payments made to it under this Agreement. 

5.2 Relationship of Parties. Nothing in this Agreement shall be deemed or construed by the parties or any third party as creating the
relationship of principal and agent, partnership or joint venture between the parties, it being understood and agreed that no provision contained herein, and no act of the parties, shall be deemed to create any relationship between the parties other
than the relationship of independent contractor nor be deemed to vest any rights, interest or claims in any third parties. 
 5.3
Integration. This Agreement (including the Exhibits hereto) contains the complete, final and exclusive agreement of the parties relating to the subject matter hereof, and supersedes all prior and contemporaneous oral and written agreements or
arrangements between the parties. To the extent this Agreement conflicts with any other agreements, written or oral, between the parties, this Agreement controls. 

5.4 Modification and Amendment. This Agreement may be modified or amended only by a writing signed by both parties. 

5.5 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California as applied
to contracts entered into entirely in California by California residents. 

  
 9 

 5.6 No Implied Licenses. No right or license is granted under this Agreement by either
party to the other, either expressly or by implication, except those specifically set forth herein.  
 5.7 Severability. If
any provision of this Agreement should be held invalid or unenforceable, the remaining provisions shall be unaffected and shall remain in full force and effect, to the extent consistent with the intent of the parties as evidenced by this Agreement
as a whole. 
 5.8 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or obligations
hereunder may be assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shall not be unreasonably withheld); provided, however, that the Company may assign this Agreement and its
rights and obligations hereunder without Kura’s consent in connection with the transfer or sale of all or substantially all of the Company’s business to which this Agreement relates to a third party, whether by merger, sale of stock, sale
of assets or otherwise. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Agreement shall
be void. 
 5.9 Headings. Section headings are for convenience of reference only and shall not be considered in the
interpretation of this Agreement. 
 5.10 Force Majeure. In the event of a delay caused by inclement weather, fire, flood, strike or
other labor dispute, act of God, act of governmental officials or agencies, or any other cause beyond the control of the parties, the party or parties so affected shall be excused from performance hereunder for the period of time attributable to
such delay, which may extend beyond the time lost due to one or more of the causes mentioned above. In the event of any such delay, the parties may, in their sole discretion, amend this Agreement, as appropriate, by mutual written agreement. 

5.11 Notices. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at
such other address as the party shall specify in writing. 
  

			
	 If to Kura:
		Kura Oncology, Inc.
			11119 N. Torrey Pines Road, Suite 125
			La Jolla, CA 92037
		
	 If to the Company:
		Araxes Pharma LLC
			11119 N. Torrey Pines Road, Suite 125
			La Jolla, CA 92037

 All notices under this Agreement shall be deemed made upon receipt by the addressee as evidenced by the
applicable written receipt or, in the case of a facsimile, as evidenced by the confirmation of transmission. 

  
 10 

 5.12 Counterparts. This Agreement may be executed in multiple counterparts, each of which
shall be deemed an original and all of which together shall constitute one and the same instrument. 
 5.13 Non-Waiver. No failure or
delay of one of the parties to insist upon strict performance of any of its rights or powers under this Agreement shall operate as a waiver thereof, nor shall any other single or partial exercise of such right or power preclude any other further
exercise of any rights or remedies provided by law. 
 5.14 Waiver of Conflicts. Each party to this Agreement acknowledges that
Cooley LLP (“Cooley”), special counsel to Kura with respect to this Agreement, has in the past represented and is now representing and may in the future represent the Company in matters unrelated to the
transactions contemplated by this Agreement (the “Services Agreement”), including representation of the Company in matters of a similar nature to the Services Agreement. The applicable rules of professional conduct
require that Cooley inform the parties hereunder of this representation and obtain their consent. Kura and the Company hereby (a) acknowledge that they are entitled to seek independent legal advice regarding the provisions of this paragraph and
the granting of the consent provided for herein, (b) acknowledge that they have had an opportunity to ask for and have obtained information relevant to such representation, including disclosure of the reasonably foreseeable adverse consequences
of such representation, (c) acknowledge that with respect to the Services Agreement, Cooley has represented solely Kura and not the Company or any stockholder, director or employee of the Company and (d) give their informed consent to
Cooley’s representation as special counsel to Kura in connection with the Services Agreement. 
 5.15 Waiver of Corporate
Opportunity. In the event that one of the parties to this Agreement or any director, officer, employee or representative of such party (the “Primary Party”) acquires knowledge of a potential transaction or other matter
(including, but not limited to, any compounds or other assets or the opportunity to acquire interests thereof) and that may be an opportunity of interest (a “Corporate Opportunity”) for the other party to this Agreement (the
“Other Party”), then the Other Party (i) renounces any expectancy that the Primary Party offer an opportunity to participate in such Corporate Opportunity to the Other Party and (ii) to the fullest extent permitted
by law, waives any claim that such opportunity constituted a Corporate Opportunity that should have been presented by the Primary Party to the Other Party or any of its affiliates. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 11 

 IN WITNESS WHEREOF, the
parties have executed this Services Agreement effective as of the date first above written. 
  

			
	KURA ONCOLOGY, INC.
		
	By:		 /s/ Troy Wilson

	Name:		 Troy Wilson

	Title:		 President & CEO

	
	ARAXES PHARMA LLC
		
	By:		 /s/ Heidi Henson

	Name:		 Heidi Henson

	Title:		 CFO

 EXHIBIT A 

SERVICES 
 1. For
purposes of this Agreement, the “Kura Key Team” shall mean the individuals listed on Schedule 1 to this Exhibit A, as may be modified by Kura from time to time in consultation with the Company. Subject to the
provisions of Section 2 of the Agreement, Kura shall use commercially reasonable efforts to provide, among others, the following Services as may be requested from time to time by the Company: 

 

	 	A.	Management Services. 

  

	 	(i)	Executive Management Services. Kura shall make available to the Company appropriate executive-level personnel to assume and perform substantially all of the day-to-day operational and executive management
responsibilities and functions related to the Company’s business, as well as provide long-term strategic planning advice and assistance to the Company. 

  

	 	(ii)	General Administrative Services. Kura shall provide general administrative services required in the ordinary course of the Company’s business which shall include, but is not limited to: (i) bookkeeping
and accounting services, including the maintenance of books and records of the Company’s financial operations in accordance with U.S. generally accepted accounting principles; (ii) reasonable management information services to the Company,
including coordination of network services and database management services, information technology planning services and procurement of general hardware and software; (iii) legal services and (iv) human resources management and support.

  

	 	(iii)	Financial and Tax Related Services. Kura shall provide to the Company the following financial services: (i) banking services administration, including bank account administration, loan administration and
arrangement of letters of credit; (ii) financial management and information services, including centralized cash management, leasing and financial analysis and (iii) tax services, including assisting the Company in the preparation of
applicable income tax returns, tax research and planning and assistance on tax audits or other tax-related controversies. 

  

	 	(iv)	Development of Intellectual Property. Kura shall assist with the development of the Company’s business and intellectual property including without limitation: (i) the prosecution and maintenance of
intellectual property and (ii) the formulation and execution of non-clinical and clinical development plans as agreed upon from time to time between Kura and the Company, but excluding Collaboration Services (as defined below).

 The Services described in clauses (i) through (iv) above are collectively referred to
as “Management Services”. 
  

	 	B.	Collaboration Services. Kura shall provide to the Company research and development services in support of the Collaboration, Option and License Agreement between the Company and Janssen Biotech, Inc., dated
February 25, 2013, as mutually agreed between the parties (“Collaboration Services”). 

  

	 	C.	Other. Kura shall provide such other Services as mutually agreed between Kura and the Company (“Other Services”). 

  
 2 

 Schedule 1 

Kura Key Team 
 (as may
be modified by Kura from time to time 
 in consultation with the Company) 

Updated as of December 8, 2014 
  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

	 	•	 	[...***...] 

  

					
			3		***Confidential Treatment Requested

 EXHIBIT B 

SERVICES FEES 
  

	1.	In consideration for the Services provided, the Company shall pay to Kura the following, subject to adjustment pursuant to Section 2 below: 

 

	 	A.	For Management Services, the Company shall pay a monthly fee of $100,000. 

  

	 	B.	For Collaboration Services, the Company shall pay Kura an amount equal to the number of FTEs (as defined below) actually expended by Kura in the course of performing Collaboration Services during the term of this
Agreement, multiplied by three hundred fifty thousand U.S. dollars ($350,000), increased annually by the percentage increase in the Consumer Price Index—Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-84 = 100,
published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States (“CPI”) as of December 31 of the then most recently ended calendar year over the
level of the CPI on December 31, 2013 (i.e., the first such increase would occur on January 1, 2014). For the purposes of this Agreement, “FTE” means the equivalent of [...***...] over a twelve (12)-month period
[...***...], which equals [...***...] per year of work in performing Collaboration Services. Kura will invoice the Company for Collaboration Services on a calendar quarter basis and will include with each invoice the number of FTEs
engaged in performing Collaboration Services during the applicable quarter. 

  

	 	C.	If the Company and Kura agree to the provision of any Other Services, the parties will mutually agree to a reasonable fee for such Services at such time. 

 

	 	D.	In addition, the Company shall reimburse Kura for its actual expenses as reasonably incurred by Kura or its employees, officers, directors, agents and/or consultants in the course of performing Services. For
Collaboration Services, the Company shall reimburse Kura for direct expenses paid or payable to any Third Parties by Kura that are incurred for services and materials in the course of performing Collaboration Services, and for the avoidance of
doubt, do not include capital expenditures. 

  

	2.	The fees for the Services set forth in Section 1 above shall be subject to the following: 

  

	 	A.	The parties acknowledge that the fees payable for the Management Services set forth in Section 1 above have been set by reference to the costs expected to be incurred by Kura in the provision of Management
Services to the Company, as calculated in accordance with generally accepted accounting principles (the “GAAP Costs”), plus a reasonable mark-up. Such charges shall be reviewed from time to time pursuant to this
Section 2 to ensure they remain consistent with this 

  

*** Confidential Treatment Registered 

	 	
standard and generally reflect comparable dealings between unrelated parties as discussed in IRC Regulation §1.482. 

 

	 	B.	The GAAP Costs shall include directly related salaries and expenses incurred, reasonably allocated indirect salaries and any other reasonably allocated indirect costs incurred by Kura in providing the Management
Services under this Agreement. 

  

	 	C.	The Service fees shall be payable in U.S. dollars (unless mutually agreed by the parties) and shall be subject to all applicable government regulations and rulings. 

 

	 	D.	Kura shall provide the Company with documentation which may be required by the revenue authorities to support the fact that the Services fees represent arm’s length remuneration for the benefits derived from
the Services provided to the Company in that particular year. 

  

	 	E.	If at any time the amount paid under this Agreement for the Services is subsequently adjusted by a tax administration for the purposes of calculating the income tax liability of either party, the parties agree that the
amount of the adjustment shall be payable and receivable by either party, as the case may be, within 90 days of the issue date of the tax assessment under which the adjustment arises. 

 

	3.	All payments hereunder shall be made in cash or by offset against any indebtedness owing to the Company by Kura. Kura shall invoice the Company at least quarterly for services provided during the previous
quarter, together with the amount of reimbursable costs and expenses incurred by Kura on behalf of the Company pursuant to Section 2.2 of the Agreement prior to such invoice. The Company agrees to pay all amounts due to Kura arising under this
Agreement promptly upon receipt of any such invoice. The parties to this Agreement agree to discuss in good faith on a semi-annual basis during the term of this Agreement the necessity or desirability of adjusting the fees set forth in this Exhibit
B. 

  

	4.	 The Company understands and acknowledges that Kura must reasonably allocate its staff resources among all of the companies to which Kura
provides services. Notwithstanding any other provision of this Agreement, Kura may at any time, without notice or liability, change or eliminate the persons who provide the Services to the Company on behalf of Kura pursuant to this Agreement,
provided that the Services continue to be provided to the Company on substantially the same levels as provided prior to such change or elimination. The Company expressly acknowledges that Kura is engaged in the business of providing drug development
services to multiple companies and providing management, scientific, business development, financial and other operational services to those companies and that neither Kura nor any other company to which Kura provides services shall have any
exclusivity or similar obligation to the Company, including without limitation any corporate opportunity obligation or any obligation to disclose or make available to the Company any information, potential transaction or other matter of

  
 2 

	 	
which any such Kura Party becomes aware otherwise than solely in the course of performing Services under this Agreement on behalf of the Company. 

  
 3 

 EXHIBIT C 

Compliance with Laws and the FCPA 
  

	1.1.	Kura shall become familiar with the FCPA, its prohibitions and purposes, and shall not undertake any actions that may violate the FCPA. Accordingly, Kura hereby agrees that: 

 

	 	(i)	no person shall be employed by it who is an official or employee of any government or any department, agency or instrumentality thereof (including, but not limited to, any health or medical providers owned or controlled
by the government); 

  

	 	(ii)	no payment or offer to pay, or the giving or offering to give, anything of value to an official or employee of any department, agency or instrumentality thereof (including, but not limited to, any health or medical
providers owned or controlled by the government), or to any political party or any candidate for political office, shall be made with the purpose of influencing any decisions favorable to either Party or its Affiliates in contravention of the FCPA
or the laws of the country in which it is providing work; 

  

	 	(iii)	it not pay, nor offer or agree to pay, nor caused to be paid, directly or indirectly, any political contributions, fees or commissions to any governmental employee or representative (including, but not limited to, any
employee of any health or medical provider owned or controlled by the government) that could cause a violation of the FCPA; 

  

	 	(iv)	it will not, directly or indirectly, in connection with the Agreement and the business resulting therefrom, offer, pay, promise to pay, or authorize the giving of money or anything of value to any governmental official
or representative, to any political party or official thereof, or to any candidate for political office, or to any person, while knowing or being aware of the probability that all or any portion of such money or thing of value will be offered,
given, or promised, directly or indirectly, to any government official, to any political party or official thereof, or to any candidate to political office, for the purpose of: 

 

	 	a.	influencing any act or decisions of such official, political party, party official, or candidate in its official capacity, including a decision to fail to perform official functions; or 

 

	 	b.	inducing such official, political party, party official, or candidate to use influence with the government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality, in
order to assist either Party in obtaining or retaining business for or with, or directing business to, any third party. 

  

	 	(v)	Kura will immediately notify the Company if it becomes aware of any apparent violation of the FCPA in connection with its activities hereunder. 

	1.2.	Kura shall provide the Company and its agents and representatives (collectively, “Agents”), as well as any regulatory authorities having regulatory oversight of Kura, with access to its facilities,
records (financial and otherwise), and supporting documentation as may be requested by any Agents in order to document or verify compliance with the provisions of this Exhibit. Kura acknowledges that the provisions of this Exhibit granting the
Company certain audit rights shall in no way relieve Kura of any of its obligations under the Agreement, nor shall such provisions require the Company to conduct any such audits. 

 

	1.3.	Kura shall maintain true and accurate records necessary to demonstrate compliance with this Agreement (including the requirements of this Exhibit). 

 

	1.4.	If Kura fails to comply with any of the provisions of this Exhibit (irrespective of the size, nature or materiality of such violation), such failure may be treated by the Company as a material breach. 

 

	1.5.	Notwithstanding anything to the contrary in the Agreement, each Party may disclose its terms and conditions (including any financial terms) to any government authority that it determines in good faith has a legitimate
need for access to such information (including, but not limited to, any governmental authorities in the U.S. or those in the country where research is being provided). 

  
 2EX-4.1

 Exhibit 4.1 

Execution Version 

REGISTRATION RIGHTS AGREEMENT 

dated as of 

May 31, 2015 
 by
and among 
 TTM TECHNOLOGIES, INC., 

HICKS, MUSE, TATE & FURST EQUITY FUND III, L.P. 

HM3 COINVESTORS, L.P. 

HMTF EQUITY FUND IV (1999), L.P. 

HMTF PRIVATE EQUITY FUND IV (1999), L.P. 

HICKS, MUSE PG-IV (1999), C.V. 

HM 4-P (1999) COINVESTORS, L.P. 

HM 4-EQ (1999) COINVESTORS, L.P. 

GSC RECOVERY II, L.P. 

and 
 GSC RECOVERY IIA,
L.P. 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
	 Article I Definitions
	  	 	1	  
				
		  	1.1	  	Definitions	  	 	1	  
		  	1.2	  	Table of Definitions	  	 	3	  
		
	 Article II Registration Rights
	  	 	4	  
				
		  	2.1	  	Demand Registration Rights	  	 	4	  
		  	2.2	  	Piggy-Back Registration	  	 	6	  
		  	2.3	  	Blackout Periods	  	 	7	  
		  	2.4	  	Registration Procedures	  	 	7	  
		  	2.5	  	Expenses	  	 	10	  
		  	2.6	  	Holdback Agreement	  	 	10	  
		
	 Article III Indemnification
	  	 	11	  
				
		  	3.1	  	Indemnification by the Company	  	 	11	  
		  	3.2	  	Indemnification by the Holders	  	 	11	  
		  	3.3	  	Notices of Claims, Etc	  	 	12	  
		  	3.4	  	Contribution	  	 	12	  
		  	3.5	  	Limitation of Holder Liability	  	 	13	  
		  	3.6	  	Other Indemnification	  	 	13	  
		  	3.7	  	Non-Exclusivity	  	 	13	  
		
	 Article IV Rule 144
	  	 	13	  
				
		  	4.1	  	Rule 144	  	 	13	  
		
	 Article V Selection Of Underwriters And Counsel
	  	 	13	  
				
		  	5.1	  	Selection of Managing Underwriters	  	 	13	  
		  	5.2	  	Selection of Counsel	  	 	13	  
		
	 Article VI Miscellaneous
	  	 	14	  
				
		  	6.1	  	Limitation on Conflicting Agreements	  	 	14	  
		  	6.2	  	Effective Date; Termination	  	 	14	  
		  	6.3	  	Amendments; Waivers	  	 	14	  
		  	6.4	  	Successors and Assigns	  	 	14	  
		  	6.5	  	Notices	  	 	14	  
		  	6.6	  	Headings	  	 	15	  
		  	6.7	  	Severability	  	 	15	  
		  	6.8	  	Counterparts	  	 	16	  
		  	6.9	  	Entire Agreement	  	 	16	  
		  	6.10	  	Governing Law; Consent to Jurisdiction; Waiver of Trial by Jury	  	 	16	  
		  	6.11	  	Specific Performance; Injunctive Relief	  	 	17	  
		  	6.12	  	Interpretation	  	 	17	  

  
 -i- 

 REGISTRATION RIGHTS AGREEMENT 

This REGISTRATION RIGHTS AGREEMENT, dated as of May 31, 2015 (this “Agreement”), is by and among (i) TTM
Technologies, Inc., a Delaware corporation (together with any successor entity thereto, the “Company”), (ii) Hicks, Muse, Tate & Furst Equity Fund III, L.P., HM3 Coinvestors, L.P., HMTF Equity Fund IV (1999), L.P.,
HMTF Private Equity Fund IV (1999), L.P., Hicks, Muse PG-IV (1999), C.V., HM 4-P (1999) Coinvestors, L.P. and HM 4-EQ (1999) Coinvestors, L.P. (together, the “HM Funds”), and (iii) GSC Recovery II, L.P. and GSC
Recovery IIA, L.P. (together, the “BD Funds”). The Company, each of the HM Funds and each of the BD Funds are sometimes referred to herein as a “Party” and collectively as the “Parties.” 

RECITALS 
 WHEREAS, the
Company, Viasystems Group, Inc., a Delaware corporation (“Viasystems”), and Vector Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), have entered into an Agreement
and Plan of Merger (as the same may be amended from time to time, the “Merger Agreement”), providing for, among other things, the merger (the “Merger”) of Merger Sub with and into Viasystems pursuant to the terms
and conditions of the Merger Agreement; 
 WHEREAS, upon the consummation of the Merger, subject to the terms of the Merger Agreement, each
of the HM Funds and the BD Funds will receive consideration that includes Common Stock (as defined below) of the Company (such Common Stock, the “Acquired Shares”), in exchange for their shares of Viasystems common stock, $0.01 par
value per share (“Viasystems Common Stock”); and 
 WHEREAS, in order to induce each of the HM Funds and the BD Funds to
enter into a voting agreement in support of the Merger (the “Voting Agreements”), prior to the consummation of the Merger the Company agreed to provide the registration rights set forth in this Agreement, which will only become
effective upon consummation of the Merger (the date of such consummation, the “Closing Date”). 
 NOW, THEREFORE, in
consideration of the premises and for other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the Parties agree as follows: 

ARTICLE I 
 DEFINITIONS

 1.1 Definitions. As used in this Agreement, the following capitalized terms shall have the following respective meanings: 

“Action” means any action, suit, arbitration, inquiry, proceeding, or investigation by or before any governmental entity.

 “Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or more
intermediaries, controls, is controlled by, or is under common control with, such specified Person, and in the case of a Person that is a private investment fund or Affiliate of a private investment funds, “Affiliate” includes any other
private investment funds or their controlled portfolio companies that are substantially related to such fund, whether by common investment advisors, managers, employees or otherwise. For the avoidance of doubt, (a) the Company shall not be
deemed to be an Affiliate of the HM Funds or the BD Funds, and none of the HM Funds will be deemed to be an Affiliate of any of the BD Funds, by virtue of the Merger Agreement, the Voting Agreements, this Agreement or any agreement in connection
with the Merger, (b) each HM Fund shall be deemed to be an Affiliate of each other HM Fund, and (c) each BD Fund shall be deemed to be an Affiliate of each other BD Fund. 

“Common Stock” means the common stock of the Company, $0.001 par value per share and any securities issuable or issued or
distributed in respect of any such shares by way of a stock dividend or 

 
stock split or in connection with a combination of shares, recapitalization, reorganization, merger, amalgamation, consolidation or otherwise. 

“Exchange Act” means the United States Securities Exchange Act of 1934, as amended, and all rules and regulations promulgated
thereunder. 
 “FINRA” means the Financial Industry Regulatory Authority. 

“Holder” means any one or more of the HM Funds or BD Funds, including their Permitted Transferees; provided,
however, that the term “Holder” shall not include (i) any HM Fund or BD Fund that ceases to own or hold any Registrable Securities, or (ii) any transferee (other than a Permitted Transferee) of shares of Common Stock
pursuant to transfer from a Holder. 
 “Permitted Transferee” means, with respect to any HM Fund or BD Fund, any Affiliate
thereof to which it Transfers (as defined in the Voting Agreement) Common Stock or Registrable Securities, as applicable. Upon the occurrence of a Transfer, such Permitted Transferee will be considered an HM Fund or BD Fund based on such status of
the transferor. 
 “Person” means any individual, partnership, firm, corporation, limited liability company, association,
trust, unincorporated organization or other entity, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. 

“Priority Period” means the ninety (90) day period commencing on the date the Company files its required Form 8-K
regarding consummation of the Merger that includes required historical and pro forma financial statements, as may be extended pursuant to the last sentence of Section 2.3. 

“Registrable Securities” means the Acquired Shares and any securities issuable or issued or distributed in respect of any
such Acquired Shares by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, reorganization, merger, amalgamation, consolidation or otherwise. For purposes of this Agreement, Registrable Securities
shall cease to be Registrable Securities when (i) a Registration Statement covering such Registrable Securities has been declared effective under the Securities Act by the SEC and such Registrable Securities have been disposed of pursuant to
such effective Registration Statement, (ii) any such Registrable Securities have been transferred to anyone other than a Permitted Transferee, or (iii) such Registrable Securities cease to be outstanding. 

“Registration Expenses” means all expenses in connection with or incident to the registration of Registrable Securities
hereunder, including (a) all SEC and any FINRA registration and filing fees and expenses, (b) all fees and expenses in connection with the registration or qualification of Registrable Securities for offering and sale under the securities
or “blue sky” laws of any state or other jurisdiction of the United States of America and, in the case of an underwritten offering, determination of their eligibility for investment under the laws of such jurisdictions as the managing
underwriter or underwriters may reasonably designate, including reasonable fees and disbursements, if any, of counsel for the underwriters in connection with such registrations or qualifications and determination, (c) all expenses relating to
the preparation, printing, distribution and reproduction of any Registration Statement required to be filed hereunder, each prospectus included therein or prepared for distribution pursuant hereto, each amendment or supplement to the foregoing, the
expenses of preparing Registrable Securities in a form for delivery for purchase pursuant to such registration or qualification and the expense of printing or producing any underwriting agreement(s) and agreement(s) among underwriters and any
“blue sky” or legal investment memoranda, any selling agreements and all other documents approved for use in writing by the Company to be used in connection with the offering, sale or delivery of Registrable Securities, (d) messenger,
telephone and delivery expenses of the Company and out-of-pocket travel expenses incurred by or for the Company’s personnel for travel undertaken for any “road show” made in connection with the offering of securities registered
thereby, (e) fees and expenses of any transfer agent and registrar with respect to the delivery of any Registrable Securities and any escrow agent or custodian 

  
 2 

 
involved in the offering, (f) fees, disbursements and expenses of counsel of the Company and independent certified public accountants of the Company incurred in connection with the
registration, qualification and offering of the Registrable Securities (including the expenses of any opinions or “comfort” letters required by or incident to such performance and compliance), (g) fees, expenses and disbursements of
counsel and any other Persons retained by the Company, including special experts retained by the Company in connection with such registration, (h) Securities Act liability insurance, if the Company desires such insurance, (i) transfer
agents’ and registrars’ fees and expenses and the fees and expenses of any other agent or trustee appointed in connection with such offering, and (j) the fees and expenses incurred by the Company and its advisers in connection with
the quotation or listing of Registrable Securities on any securities exchange or automated securities quotation system. Notwithstanding the foregoing, any (x) fees and expenses of any legal counsel or other advisors to a Holder and any other
out-of-pocket expenses of a Holder, (y) brokerage commissions attributable to the sale of any of the Registrable Securities, and (z) commissions, fees, discounts, transfer taxes or stamp duties and expenses of any underwriter or placement
agent applicable to Registrable Securities offered for a Holder’s account in accordance with this Agreement shall not be “Registration Expenses.” 

“Registration Statement” means a Demand Registration Statement or a Piggy-Back Registration Statement, as the case may be.

 “SEC” means the United States Securities and Exchange Commission, or any successor thereto. 

“Securities Act” means the United States Securities Act of 1933, as amended, and all rules and regulations promulgated
thereunder. 
 “Tangs” means (a) Su Sih (BVI) Limited, a corporation organized under the laws of the British Virgin
Islands,, and (b) Tang Hsiang Chien, an individual, together with their respective Affiliates. 
 1.2 Table of Definitions. The
following terms have the meanings set forth in the Sections set forth below: 
  

			
	 Term
	  	Section
	 Acquired Shares
	  	Recitals
	 Agreement
	  	Preamble
	 BD Funds
	  	Preamble
	 Blackout Period
	  	2.3
	 Closing Date
	  	Recitals
	 Commitment Period
	  	2.1(d)
	 Company
	  	Preamble
	 Company Indemnified Parties
	  	3.2
	 Company Indemnified Party
	  	3.2
	 Demand Registration
	  	2.1(a)
	 Demand Registration Statement
	  	2.1(a)
	 Exercising Holder
	  	2.1(a)
	 HM Funds
	  	Preamble
	 Holdback Period
	  	2.6(a)
	 Indemnified Parties
	  	3.2
	 Indemnified Party
	  	3.2
	 Maximum Offering Size
	  	2.1(b)
	 Merger
	  	Recitals
	 Merger Agreement
	  	Recitals
	 Merger Sub
	  	Recitals
	 Non-Exercising Holders
	  	2.1(b)
	 Participating Piggy-Back Holders
	  	2.2(b)
	 Parties
	  	Preamble

  
 3 

			
	 Term
	  	Section
	 Party
	  	Preamble
	 Piggy-Back Registration
	  	2.2(a)
	 Piggy-Back Registration Statement
	  	2.2(a)
	 Seller Indemnified Parties
	  	3.1
	 Seller Indemnified Party
	  	3.1
	 Viasystems
	  	Recitals
	 Viasystems Common Stock
	  	Recitals
	 Voting Agreements
	  	Recitals

 ARTICLE II 

REGISTRATION RIGHTS 
 2.1
Demand Registration Rights. 
 (a) During the Priority Period and, subject to and in accordance with Section 2.1(c) and (d),
during the Commitment Period (as defined herein), each Holder (such Holder, together with its Affiliates, the “Exercising Holder”) shall be entitled to request in writing that the Company effect a registration (a “Demand
Registration”) under the Securities Act, including in an underwritten public offering, covering the registration of some or all of such Holder’s Registrable Securities, and which request shall specify the number of Registrable
Securities for which registration is requested and the intended method or methods of distribution thereof. Upon receipt of a request for a Demand Registration and until the completion of the offer of the Registrable Securities covered by such Demand
Registration, the Company shall (i) use reasonable efforts to, as soon as reasonably practicable, after receipt of such written request, file with the SEC and use reasonable efforts to cause to be declared effective, a registration statement (a
“Demand Registration Statement”) relating to all of the Registrable Securities that the Company has been so requested to register for sale, to the extent required to permit the disposition (in accordance with the intended method or
methods of distribution thereof) of the Registrable Securities so registered, (ii) if the Demand Registration relates to an underwritten public offering, use reasonable efforts to support such Demand Registration (including through
participation of the Company’s Chief Executive Officer and Chief Financial Officer in customary “road show” meetings with prospective purchasers of Registrable Securities), (iii) not permit the exercise by the Tangs of any
registration demand and not file any registration statement in connection with any demand made by the Tangs prior to the expiration of the Priority Period, and (iv) otherwise provide for “clear markets.” 

(b) If (i) the request for the Demand Registration occurs during the Priority Period, and (ii) the Demand Registration relates to an
underwritten public offering and the managing underwriter of such proposed public offering advises the Company and the Exercising Holder that, in its reasonable opinion, the number of Registrable Securities requested to be included in the Demand
Registration (including securities to be sold by the Company or any other security holder, including any Holders other than the Exercising Holder (such Holders, the “Non-Exercising Holders”)) exceeds the largest number of securities
which reasonably can be sold in such offering without having a material adverse effect on such offering, including the price at which such securities can be sold (the “Maximum Offering Size”), then the Company shall include in such
Demand Registration, up to the Maximum Offering Size, first, (1) the Registrable Securities the Exercising Holder proposes to register, (2) the Registrable Securities any Non-Exercising Holder proposes to register, (3) any securities
with respect to which the Tangs have requested registration, and (4) any securities the Company proposes to register and any securities with respect to which any other security holder (other than the Tangs) has requested registration. If the
securities requested to be registered pursuant to the preceding clauses (1), (2), and (3) exceed the Maximum Offering Size, then the number of securities to be sold by each HM Fund, each BD Fund, and each of the Tangs shall be allocated among
such selling security holders on a pro rata basis (based on the number of shares of Common Stock held by each such selling security holder and its Affiliates). The Company represents and warrants to the HM Funds and the BD Funds that it has not
entered, and agrees with them that it shall not hereafter enter, into any agreement which is inconsistent with the rights of priority provided in this Section 2.1. 

  
 4 

 (c) The HM Funds shall collectively be entitled to one (1) Demand Registration during the
Priority Period and the BD Funds shall collectively be entitled to one (1) Demand Registration during the Priority Period. Notwithstanding anything herein to the contrary, a Demand Registration shall not be deemed to have been effected for
purposes of this Section 2.1 unless (A) the Demand Registration Statement relating thereto has become effective under the Securities Act and the Registrable Securities included in such Demand Registration Statement have actually
been sold thereunder, (B) the Demand Registration Statement relating thereto has remained effective for at least the period set forth in Section 2.4(a) and (C) the offering of Registrable Securities pursuant to such
Registration Demand is not subject to, or interfered with by, any stop order, injunction or other order or requirement of the SEC or other governmental agency. The Company shall bear and pay all Registration Expenses (as provided in
Section 2.5); provided, however, that in the event the Exercising Holder revokes a Demand Registration request (which revocation may only be made prior to the Company requesting acceleration of effectiveness of the Demand
Registration Statement) then such Demand Registration shall count as having been effected for the purposes of this Section 2.1 unless the Exercising Holder pays all Registration Expenses in connection with such revoked Demand
Registration within seven (7) days of written request therefor by the Company. 
 (d) If (i) none of the HM Funds requests a
Demand Registration during the Priority Period pursuant to Section 2.1(a) or otherwise a Demand Registration was not effected as provided in Section 2.1(c), or (ii) the HM Funds are not able to sell the number of
Registrable Securities requested by them to be included in such Demand Registration due to the reductions provided in Section 2.1(b), then the HM Funds shall collectively be entitled to one (1) additional Demand Registration
pursuant to this Section 2.1(d) during the two-year period following the expiration of the Priority Period (such period, as may be extended pursuant to the last sentence of Section 2.3, the “Commitment
Period”). If (x) none of the BD Funds requests a Demand Registration during the Priority Period pursuant to Section 2.1(a) or otherwise a Demand Registration was not effected as provided in Section 2.1(c), or
(y) the BD Funds are not able to sell the number of Registrable Securities requested by them to be included in such Demand Registration due to the reductions provided in Section 2.1(b), then the BD Funds shall collectively be
entitled to one (1) additional Demand Registration pursuant to this Section 2.1(d) during the Commitment Period. 
 (e) If
(i) the request for the Demand Registration occurs after the Priority Period pursuant to Section 2.1(d), and (ii) the Demand Registration relates to an underwritten public offering and the managing underwriter of such proposed
public offering advises the Company and the Exercising Holder that, in its reasonable opinion, the number of Registrable Securities requested to be included in the Demand Registration (including securities to be sold by the Company or any
Non-Exercising Holders) exceeds the Maximum Offering Size, then the Company shall include in such Demand Registration, up to the Maximum Offering Size, first, (1) the Registrable Securities the Exercising Holder proposes to register, and
(2) the Registrable Securities any Non-Exercising Holder proposes to register; second, any securities with respect to which the Tangs have requested registration, and, third, any securities the Company proposes to register and any securities
with respect to which any other security holder (other than the Tangs) has requested registration. If the securities requested to be registered pursuant to the preceding clauses (1) and (2) exceed the Maximum Offering Size, then the number
of securities to be sold by each HM Fund and each BD Fund shall be allocated among such selling security holders on a pro rata basis (based on the number of shares of Common Stock held by each such Holder); provided, however, that if
the number of securities to be sold by the BD Funds or HM Funds, as the case may be, in such sale is less than 66 2⁄3% of the number of securities requested to
be registered thereby, such Demand Registration shall not count as one of the permitted Demand Registrations. 
 (f) Notwithstanding
anything to the contrary contained herein, the Company shall not be required to prepare and file any Demand Registration Statement within one hundred and eighty (180) days following the date of effectiveness of any other Registration Statement.

  
 5 

 2.2 Piggy-Back Registration. 

(a) During the Commitment Period, if the Company proposes to file on its behalf and/or on behalf of any holder of its securities a registration
statement under the Securities Act on any form (other than a registration statement on Form S-4, F-4 or S-8 (or any successor form) for securities to be offered in a transaction of the type referred to in
Rule 145 under the Securities Act or to employees of the Company pursuant to any employee benefit plan, respectively) for the registration of Common Stock (a “Piggy-Back Registration”),
it shall give written notice to all Non-Exercising Holders at least thirty (30) days before the initial filing with the SEC of such registration statement (a “Piggy-Back Registration Statement”), which notice shall set forth
the number of shares of Common Stock that the Company, Exercising Holders, and other holders of Common Stock, if any, then contemplate including in such registration and the intended method of disposition of such Common Stock. 

(b) If any Holder desires to have Registrable Securities registered under this Section 2.2 (along with any other security holders
entitled to participate in the Piggy-Back Registration on the date of this Agreement and exercising such right, the “Participating Piggy-Back Holders”), it shall advise the Company in writing within five (5) days after the date
of receipt of such notice from the Company of its desire to have Registrable Securities registered under this Section 2.2, and shall set forth the number of Registrable Securities for which registration is requested. The Company shall
thereupon use reasonable efforts to include, or in the case of a proposed underwritten public offering, use reasonable efforts to cause the managing underwriter or underwriters to permit such Holder to include, in such filing the number of
Registrable Securities for which registration is so requested, subject to paragraph (c) below, and shall use reasonable efforts to effect registration of such Registrable Securities under the Securities Act. 

(c) If the Piggy-Back Registration relates to an underwritten public offering and the managing underwriter of such proposed public offering
advises the Company and the Holders that, in its reasonable opinion, the number of Registrable Securities requested to be included in the Piggy-Back Registration together with the securities being registered by the Company or any other security
holder exceeds the Maximum Offering Size, then: 
 (i) in the event the Company initiated the Piggy-Back Registration, the Company shall
include in such Piggy-Back Registration first, the securities the Company proposes to register, second, the securities the Tangs propose to register, third, the securities the Holders propose to register, and fourth, the securities all other selling
security holders propose to register; provided, however, that each group shall be excluded in the preceding order of priority and, if the securities proposed to be registered by any such group are not completely excluded, then the
securities available to be registered for such group shall be allocated among such selling security holders on a pro rata basis (based on the number of shares of Common Stock held by each such selling security holder); 

(ii) in the event the Tangs initiated the Piggy-Back Registration, the Company shall include in such Piggy-Back Registration first, the
securities the Tangs propose to register, second, the securities the Holders propose to register, third, the securities the Company proposes to register, and fourth, the securities all other selling security holders propose to register;
provided, however, that each group shall be excluded in the preceding order of priority and, if the securities proposed to be registered by any such group are not completely excluded, then the securities available to be registered for
such group shall be allocated among such selling security holders on a pro rata basis (based on the number of shares of Common Stock held by each such selling security holder); 

(iii) in the event any Holder initiated the Piggy-Back Registration, the Company shall include in such Piggy-Back Registration first, the
securities the Holders propose to register, second, the securities the Tangs propose to register, third, the securities any other Participating Piggy-Back Holder proposes to register, and fourth, any securities the Company proposes to register;
provided, however, that each group shall be excluded in the preceding order of priority and, if the securities proposed to be registered by any such group are not completely excluded, then the securities available to be registered for
such group shall be allocated among such selling security holders on a pro 

  
 6 

 
rata basis (based on the number of shares of Common Stock held by each such selling security holder); and 

(iv) in the event any other Participating Piggy-Back Holders initiated the Piggy-Back Registration, the Company shall include in such
Piggy-Back Registration first, the securities the Tangs and the Holders propose to register, second, the securities the Company proposes to register, and third, the securities all other selling security holders propose to register; provided,
however, that each group shall be excluded in the preceding order of priority and, if the securities proposed to be registered by any such group are not completely excluded, then the securities available to be registered for such group shall
be allocated among such selling security holders on a pro rata basis (based on the number of shares of Common Stock held by each such selling security holder.) 

(d) The Company represents and warrants to the HM Funds and the BD Funds that it has not entered, and agrees with them that it shall not
hereafter enter, into any agreement that is inconsistent with the rights of priority provided in this Section 2.2. 
 2.3
Blackout Periods. The Company shall have the right to delay the filing or effectiveness of a Registration Statement required pursuant to Section 2.1 or 2.2 hereof during no more than two (2) periods aggregating to not
more than one hundred and twenty (120) days in any twelve-month period (each, a “Blackout Period”), in the event that (i) the Company would, in the good faith judgment of the Company’s board of directors, be required
to disclose in the prospectus information not otherwise then required by law to be publicly disclosed and (ii) in the good faith judgment of the Company’s board of directors, there is a reasonable likelihood that such disclosure, or any
other action to be taken in connection with the prospectus, would materially and adversely affect or interfere with any significant financing, acquisition, merger, disposition of assets, corporate reorganization or other material transaction or
negotiations involving the Company; provided, however, that (A) a Holder shall be entitled, at any time after receiving notice of such delay and before such Demand Registration Statement becomes effective, to withdraw such request
and, if such request is withdrawn, such Demand Registration shall not count as one of the permitted Demand Registrations and (B) the Company shall delay during such Blackout Period the filing or effectiveness of any Registration Statement
required pursuant to the registration rights of other holders of any securities of the Company. The Company shall promptly give the Holders written notice of such determination containing, to the extent permitted by law, a general statement of the
reasons for such postponement and an approximation of the anticipated delay. After the expiration of any Blackout Period (including upon public disclosure of the information that was the reason for such Blackout Period) and without any further
request from any Holder, the Company shall (subject to there being no other Blackout period) promptly notify the Holders and shall use reasonable efforts to prepare and file with the SEC the requisite Registration Statement or such amendments or
supplements to such Registration Statement or prospectus used in connection therewith as may be necessary to cause such Registration Statement to become effective as promptly as practicable thereafter. Notwithstanding anything herein to the
contrary, (i) the Priority Period shall automatically be extended by the duration of any Blackout Periods occurring during the Priority Period and, if any Holder has exercised a Demand Registration, thereafter until the completion of the offer
of the Registrable Securities covered by any such Demand Registration, and (ii) the Commitment Period shall automatically be extended by the duration of any Blackout Periods occurring during the Commitment Period. 

2.4 Registration Procedures. If the Company is required by the provisions of Section 2.1 or 2.2 to use reasonable
efforts to effect the registration of any of its securities under the Securities Act, the Company shall, as soon as reasonably practicable, after receipt of a written request for a Demand Registration: 

(a) prepare and file with the SEC a Registration Statement with respect to such securities and use reasonable efforts to cause such
Registration Statement to become effective as promptly as practicable and to remain effective for a period of time required for the disposition of such Registrable Securities by the Holders thereof but not to exceed ninety (90) days excluding
any days that fall during a permitted Blackout Period under Section 2.3; provided, however, that before filing such Registration Statement or any amendments or supplements thereto, the Company shall, if requested,

  
 7 

 
furnish to counsel selected by the Holders copies of all documents proposed to be filed, which documents shall be subject to the review of such counsel, and shall in good faith consider
incorporating in each such document such changes as such counsel to the Holders reasonably and in a timely manner may suggest; provided, however, that the Company shall not have any obligation to so modify any information; 

(b) prepare and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in connection
therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to the sale or other disposition of all securities covered by such Registration Statement until the
earlier of such time as all of such securities have been disposed of in a public offering or the expiration of ninety (90) days (excluding any days that fall during a permitted Blackout Period under Section 2.3); 

(c) furnish to such selling security holders such number of conformed copies of the applicable Registration Statement and each such amendment
and supplement thereto (including in each case all exhibits), such number of copies of the prospectus contained in such Registration Statement (including each preliminary prospectus and any summary prospectus) and any other prospectus, in conformity
with the requirements of the Securities Act, and such other documents, as such selling security holders may reasonably request; 
 (d) use
reasonable efforts to register or qualify the Registrable Securities or other securities covered by such Registration Statement under such other securities or blue sky laws of such jurisdictions within the United States and its territories and
possessions as each Holder of such Registrable Securities shall reasonably request, to keep such registration or qualification in effect for so long as such Registration Statement remains in effect or until all of the Registrable Securities are
sold, whichever is shorter, and to take any other action which may be reasonably necessary or advisable to enable the Holder to consummate the disposition in such jurisdictions of the securities owned by such Holder (provided, however,
that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business as a foreign corporation, subject itself to taxation in or to file a general consent to service of process in any jurisdiction where
it would not, but for the requirements of this paragraph (d), be obligated to do so) and do such other reasonable acts and things as may be required of it to enable such Holder to consummate the disposition in such jurisdiction of the securities
covered by such Registration Statement; 
 (e) use reasonable efforts to furnish, at the request of any Holder requesting registration of
Registrable Securities pursuant to Section 2.1 or 2.2, if the method of distribution is by means of an underwriting, on the date that the shares of Registrable Securities are delivered to the underwriters for sale pursuant to such
registration, or if such Registrable Securities are not being sold through underwriters, on the date that the registration statement with respect to such shares of Registrable Securities becomes effective, (1) a signed opinion (including
disclosure statement), dated such date, of the independent legal counsel representing the Company for the purpose of such registration, addressed to the underwriters, if any, and if such Registrable Securities are not being sold through
underwriters, then to the Holders making such request, and (2) letters dated such date and the date the offering is priced from the independent certified public accountants of the Company, addressed to the underwriters, if any, and if such
Registrable Securities are not being sold through underwriters, then to the Holders making such request, in each case, in customary form and covering such matters of the kind customarily covered by opinions or comfort letters, as the case may be, in
such a transaction; 
 (f) enter into customary agreements (including if the method of distribution is by means of an underwriting, an
underwriting agreement containing representations, warranties and indemnities in customary form) and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such Registrable Securities; 

(g) otherwise use reasonable efforts to comply with all applicable rules and regulations promulgated by the SEC; 

  
 8 

 (h) use reasonable efforts to cause all such Registrable Securities to be listed on each
securities exchange or quotation system on which the Common Stock is listed or traded; 
 (i) give written notice to the Holders: 

(i) when such Registration Statement, the prospectus or any amendment or supplement thereto has been filed with the SEC and when such
Registration Statement or any post-effective amendment thereto has become effective; 
 (ii) of any request by the SEC for amendments or
supplements to such Registration Statement or the prospectus included therein or for additional information; 
 (iii) of the issuance by
the SEC of any stop order suspending the effectiveness of such Registration Statement or the initiation of any proceedings for that purpose; 

(iv) of the receipt by the Company or its legal counsel of any notification with respect to the suspension of the qualification of the Common
Stock for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and 
 (v) of the happening of any
event that requires the Company to make changes in such Registration Statement or such prospectus in order to make the statements therein, in light of the circumstances in which they were made, not misleading (which notice shall be accompanied by an
instruction to suspend the use of such prospectus until the requisite changes have been made); 
 (j) use reasonable efforts to obtain the
withdrawal of any order suspending the effectiveness of such Registration Statement at the earliest possible time; 
 (k) furnish to each
Holder, without charge, at least one copy of such Registration Statement and any post-effective amendment thereto, including financial statements and schedules, and, if the Holder so requests in writing, all exhibits (including those, if any,
incorporated by reference); 
 (l) upon the occurrence of any event contemplated by Section 2.4(i)(v) above, promptly prepare a
post-effective amendment to such Registration Statement or a supplement to the related prospectus or file any other required document so that, as thereafter delivered to the Holders, the prospectus shall not contain an untrue statement of a material
fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holders in accordance with Section 2.4(i)(v) above to
suspend the use of the prospectus until the requisite changes to the prospectus have been made, then the Holders shall suspend use of such prospectus and use reasonable efforts to return to the Company all copies of such prospectus other than
permanent file copies then in such Holders’ possession, and the period of effectiveness of such Registration Statement provided for above shall be extended by the number of days from and including the date of the giving of such notice to the
date the Holders shall have received such amended or supplemented prospectus pursuant to this Section 2.4(l); 
 (m) subject to
the execution of confidentiality agreements satisfactory in form and substance to the Company, pursuant to the reasonable request of the Holder or underwriters, make reasonably available for inspection by representatives of the Holders, any
underwriter participating in any disposition pursuant to such Registration Statement, and any attorney, accountant or other agent retained by such representative or any such underwriter all relevant financial and other records, pertinent corporate
documents and properties of the Company and its subsidiaries and cause the officers, directors and employees of the Company and its subsidiaries to supply all relevant information reasonably requested by such representative or any such underwriter,
attorney, accountant or agent in connection with the registration provided that any such information inspected or discussions conducted shall be done in a manner so as not to unreasonably disrupt the operation of the Company’s business; 

  
 9 

 (n) in connection with any underwritten offering to the extent the underwriters determine that
the failure to do so would have a material adverse effect on such offering, make appropriate officers and senior executives of the Company reasonably available to the selling security holders for meetings with prospective purchasers of Registrable
Securities and prepare and present to potential investors customary “road show” material in each case in accordance with the recommendations of the underwriters and in all respects in a manner reasonably requested and consistent with other
new issuances of securities in an offering of a similar size to such offering of the Registrable Securities; and 
 (o) use reasonable
efforts to procure the cooperation of the Company’s transfer agent in settling any offering or sale of Registrable Securities, including with respect to the transfer of physical stock certificates into book-entry form in accordance with any
procedures reasonably requested by the Holders or the underwriters, if any. 
 It shall be a condition precedent to the obligation of the
Company to take any action pursuant to this Agreement in respect of the Registrable Securities which are to be registered at the request of any Holder that such Holder shall furnish to the Company such information regarding the Registrable
Securities held by such Holder and the intended method of distribution thereof as the Company shall reasonably request and as shall be required in connection with the action taken by the Company. 

2.5 Expenses. Except as otherwise agreed or set forth herein, the Company shall bear and pay all Registration Expenses, and Holders
shall bear and pay all (x) fees and expenses of any legal counsel or other advisors to such Holder and any other out-of-pocket expenses of such Holder, (y) brokerage commissions attributable to the sale of any of the Registrable
Securities, and (z) commissions, fees, discounts, transfer taxes or stamp duties and expenses of any underwriter or placement agent applicable to Registrable Securities offered for a Holder’s account in accordance with this Agreement. 

2.6 Holdback Agreement. 

(a) In the case of an underwritten offering of securities by the Company with respect to which the Company has complied with its obligations
hereunder, each Holder agrees, if and to the extent (i) requested by the managing underwriter of such underwritten offering and (ii) all of the Company’s named executive officers and directors execute agreements identical to those
referred to in this Section 2.6, that it shall not during the period beginning on, and ending ninety (90) days (subject to one extension of no more than 17 days if required by the underwriters in connection with FINRA
Rule 2711(f)(2) or any similar or successor provision) (or such shorter period as may be permitted by such managing underwriter) after, the effective date of the registration statement filed in connection with such Registration (the
“Holdback Period”), except for Registrable Securities included in such registration or as otherwise agreed between such Holder and such managing underwriter, (i) lend, offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable
or exchangeable for Common Stock held immediately prior to the effectiveness of the Registration Statement for such offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise; provided, however, that
such restrictions shall not apply to any such sales, purchases, grants, transfers, dispositions, or arrangements to settle or otherwise close any hedging instruments that were outstanding prior to the beginning of the Holdback Period unless the
Holder of such Registrable Securities had proposed to sell Registrable Securities in the offering and provided, further, that such restrictions shall not apply to any transfers of direct or indirect economic or ownership interests in
such Holder. No Holder subject to this Section 2.6 or any of the Company’s executive officers and directors that execute agreements identical to those referred to in this Section 2.6 shall be released from any obligation
under any agreement, arrangement or understanding entered into pursuant to or contemplated by this Section 2.6 unless all Holders are also released from their obligations under Section 2.6. In the event of any such release
the Company shall notify the Holders of any such release within three (3) business days 

  
 10 

 
after such release. If requested by the managing underwriter, each Holder shall enter into a lock-up agreement with the applicable underwriters that is consistent with the agreement in this
Section 2.6. 
 (b) In order to enforce the foregoing covenant, the Company may impose stop transfer instructions with respect
to the Registrable Securities of each Holder (and the shares or securities of every other Person subject to the foregoing restriction) to the extent transfers are so restricted, until the end of such period. 

ARTICLE III 

INDEMNIFICATION 
 3.1
Indemnification by the Company. The Company will, and it hereby does, indemnify and hold harmless, to the extent permitted by law, the seller of any Registrable Securities covered by each registration statement filed by the Company to which
Article II applies, each affiliate of such seller and their respective trustees, directors, and officers or general and limited partners (including any director, officer, affiliate, employee, representative, agent, and controlling Person
of any of the foregoing, within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), each other Person who participates as an underwriter in the offering or sale of such securities and each other Person, if
any, who controls such seller or any such underwriter within the meaning of the Securities Act (each, a “Seller Indemnified Party”, and collectively, the “Seller Indemnified Parties”), against any and all Actions
(whether or not a Seller Indemnified Party is a party thereto), losses, claims, damages, or liabilities, joint or several, and expenses (including, without limitation, reasonable attorney’s fees and reasonable expenses of investigation) to
which such Seller Indemnified Party becomes subject under the Securities Act, common law, or otherwise, insofar as such losses, claims, damages, liabilities, or expenses (or actions or proceedings in respect thereof, whether or not such Seller
Indemnified Party is a party thereto) arise out of, relate to, or are based upon (a) any untrue statement or alleged untrue statement of any material fact contained in any such registration statement, any preliminary, final, or supplemental
prospectus contained therein, or any amendment or supplement thereto or any issuer free-writing prospectus relating to any sale or distribution pursuant thereto, or (b) any omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein (in the case of a prospectus, in light of the circumstances under which they were made) not misleading, and the Company will reimburse such Seller Indemnified Party for any legal or
any other expenses reasonably incurred by such Seller Indemnified Party in connection with investigating or defending against any such loss, claim, liability, action, or proceeding; provided, that the Company shall not be liable to any Seller
Indemnified Party in any such case to the extent that any such loss, claim, damage, liability (or action or proceeding in respect thereof), or expense arises out of or is based upon any untrue statement or alleged untrue statement or omission or
alleged omission made in such registration statement or amendment or supplement thereto or in any such preliminary, final, or supplemental prospectus or issuer free-writing prospectus in reliance upon and in conformity with written information
furnished to the Company through an instrument duly executed by such seller specifically stating that it is for use in the preparation thereof. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
of the Company or any of the prospective sellers, or any of their respective affiliates, directors, officers, or controlling Persons and shall survive the transfer of such securities by such seller. 

3.2 Indemnification by the Holders. The Company may require, as a condition to including any Registrable Securities in any registration
statement to which Article II applies, that the Company shall have received an undertaking reasonably satisfactory to it from the prospective seller of such Registrable Securities or any underwriter to indemnify and hold harmless (in the
same manner and to the same extent as set forth in Section 3.1) the Company, its directors, officers, affiliates, employees, representatives, agents, and controlling Persons (each, a “Company Indemnified Party,” and
collectively, the “Company Indemnified Parties,” and together with the Seller Indemnified Parties, the “Indemnified Parties” and each individually an “Indemnified Party”) with respect to any untrue
statement or alleged untrue statement in or omission or alleged omission from such registration statement, any preliminary, final or supplemental prospectus contained therein, or any amendment or supplement, if such untrue statement or alleged
untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company through an instrument duly executed by such seller or 

  
 11 

 
underwriter respectively, specifically stating that it is for use in the preparation of such registration statement, preliminary, final, or supplemental prospectus or amendment or supplement, or
a document incorporated by reference into any of the foregoing; provided, however, that the indemnity agreement contained in this Section 3.2 shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of such seller (which consent shall not be unreasonably withheld or delayed). Such indemnity shall remain in full force and effect regardless of any investigation made by or on
behalf of the Company or any of the prospective sellers, or any of their respective affiliates, directors, officers, or controlling Persons and shall survive the transfer of such securities by such Holder. 

3.3 Notices of Claims, Etc. Promptly after receipt by an Indemnified Party hereunder of written notice of the commencement of
any Action with respect to which a claim for indemnification may be sought pursuant to this Article III, such Indemnified Party will, if a claim in respect thereof is to be made against an indemnifying party, give prompt written notice
to the latter of the commencement of such Action; provided that the failure of the Indemnified Party to give prompt notice as provided herein (i) shall not relieve the indemnifying party of its obligations under this Article III,
except to the extent that the indemnifying party is materially prejudiced by such failure to give prompt notice, and (ii) shall not, in any event, relieve the indemnifying party from any obligations which it may otherwise have to any
Indemnified Party in addition to any indemnification obligation provided in Sections 3.1 and 3.2. In case any such Action is brought against an Indemnified Party, unless in such Indemnified Party’s reasonable judgment a
conflict of interest between such Indemnified Party and indemnifying parties may exist in respect of such Action, the indemnifying party will be entitled to participate in and to assume the defense thereof (at its expense), jointly with any other
indemnifying party similarly notified to the extent that it may wish, with counsel reasonably satisfactory to such Indemnified Party, and after notice from the indemnifying party to such Indemnified Party of its election so to assume the defense
thereof, the indemnifying party will not be liable to such Indemnified Party for any legal or other expenses subsequently incurred by the latter in connection with the defense thereof other than reasonable costs of investigation. No indemnifying
party will consent to entry of any judgment or settle any Action which (i) does not include, as an unconditional term thereof, the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such
Action, and (ii) does not involve the imposition of equitable remedies or of any obligations on such Indemnified Party and does not otherwise adversely affect such Indemnified Party, other than as a result of the imposition of financial
obligations for such Indemnified Party that will be indemnified hereunder. 
 3.4 Contribution. 

(a) If the indemnification provided for in this Article III from the indemnifying party is unavailable to or insufficient to fully
hold harmless an Indemnified Party hereunder in respect of any Action, losses, damages, liabilities, or expenses referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such Action, losses, damages, liabilities, or expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and such Indemnified Party in connection with the
actions which resulted in such Action losses, damages, liabilities, or expenses, as well as any other relevant equitable considerations. The relative fault of such indemnifying party and such Indemnified Party shall be determined by reference to,
among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such
indemnifying party or Indemnified Parties, and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such action. The amount paid or payable by a party under this Section 3.4 as a
result of the Action, losses, damages, liabilities, and expenses referred to above shall be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with any investigation or proceeding. 

(b) The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 3.4 were determined
by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in Section 3.4(a) hereof. No 

  
 12 

 
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation. 
 3.5 Limitation of Holder Liability. Notwithstanding any other provisions of this Agreement, the
aggregate liability of a Holder under this Article III shall be limited to the aggregate net proceeds received by such seller in connection with any offering to which such registration under the Securities Act relates. 

3.6 Other Indemnification. Indemnification similar to that specified in the preceding provisions of this Article III (with
appropriate modifications) shall be given by the Company and each Holder of Registrable Securities with respect to any required registration or other qualification of securities under any federal or state law or regulation or governmental authority
other than the Securities Act. 
 3.7 Non-Exclusivity. The obligations of the Parties under this Article III shall be in
addition to any liability which any Party may otherwise have to any other Party. 
 ARTICLE IV 

RULE 144 
 4.1 Rule
144. The Company covenants that it will use reasonable efforts to (a) file the reports required to be filed by it under the Securities Act and the Exchange Act (or, if the Company is not required to file such reports, it will, upon the
request of any Holder, make publicly available such information), and it will take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder to sell Registrable Securities without
registration under the Securities Act within the limitation of the exemptions provided by (i) Rule 144 under the Securities Act, as such Rule may be amended from time to time, or (ii) any similar rule or regulation hereafter adopted by the
SEC; and (b) file with or furnish to the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act. Upon the request of any Holder of Registrable Securities, the Company will
deliver to such Holder a written statement as to whether it has complied with such requirements. 
 ARTICLE V 

SELECTION OF UNDERWRITERS AND COUNSEL 

5.1 Selection of Managing Underwriters. In the event the Holders have requested an underwritten offering pursuant to
Section 2.1, the underwriter or underwriters shall be selected by the Company, subject to consultation with and the approval of the Holders of a majority of the shares being so registered, which approval shall not be unreasonably
withheld or delayed. In that event, (i) all of the representations and warranties by, and the other agreements on the part of, the Company to and for the benefit of such underwriters shall also be made to and for the benefit of such Holders of
Registrable Securities, (ii) any or all of the conditions precedent to the obligations of such underwriters under such underwriting agreement shall be conditions precedent to the obligations of such Holders of Registrable Securities, and
(iii) no Holder shall be required to make any representations or warranties to or agreements with the Company or the underwriters other than representations, warranties or agreements regarding such Holder, the Registrable Securities of such
Holder and such Holder’s intended method of distribution and any other representations customarily required or required by law. Subject to the foregoing, all Holders proposing to distribute Registrable Securities through such underwritten
offering shall enter into an underwriting agreement in customary form with the underwriter or underwriters. 
 5.2 Selection of
Counsel. In connection with any registration of Registrable Securities pursuant to Article II hereof, the Holders of a majority of the Registrable Securities (on an as converted basis) covered by any such registration may select one
firm (at the Holders’ expense) as counsel to represent all Holders of Registrable Securities covered by such registration; provided, however, that in the event that the counsel selected as provided above is also acting as counsel
to the Company in connection with such registration, the remaining Holders shall be entitled to select one additional firm as counsel to represent all such remaining Holders at such remaining Holders’ expense. 

  
 13 

 ARTICLE VI 

MISCELLANEOUS 
 6.1
Limitation on Conflicting Agreements. From and after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company which conflicts with, or constitutes (or
upon performance in accordance with its terms would constitute) a breach of, the Company’s obligations under this Agreement. 
 6.2
Effective Date; Termination. This Agreement shall be effective as of the Closing Date, and if the Merger Agreement is terminated in accordance with its terms, then this Agreement shall terminate and be null and void ab initio. After
the Closing Date, this Agreement will terminate upon the earliest to occur of (a) the date upon which there shall be no Registrable Securities as a result of the events set forth in subsections (i) through (iii) of the definition of
Registrable Securities set forth herein, or (b) at the expiration of the Commitment Period; provided, however, that if any Holder has exercised a Demand Registration or Piggy-Back Registration demand pursuant to
Section 2.1 or Section 2.2, as the case may be, this Agreement shall only terminate upon the completion of the applicable offering; provided, further, that the provisions of Article III and Article
VI of this Agreement shall survive. Upon termination pursuant to this Section 6.2, the Company will no longer be obligated to provide notice of a proposed registration. Each Holder shall notify the Company if such Holder no longer
owns any Registrable Securities, within 30 days of the occurrence of such event. 
 6.3 Amendments; Waivers. 

(a) No failure or delay on the part of any Party in exercising any right, power, or privilege hereunder will operate as a waiver thereof, nor
will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power, or privilege. 

(b) Any provision of this Agreement may be amended or waived if, but only if, such amendment or waiver is in writing and signed by all
Parties. 
 6.4 Successors and Assigns. All the terms and provisions of this Agreement shall be binding upon and inure to the benefit
of and be enforceable by the Parties and the successors of each Party and Permitted Transferees, whether so expressed or not. Other than Transfers to Permitted Transferees, none of the Parties may assign any of its rights or obligations hereunder,
in whole or in part, by operation of law or otherwise, without the prior written consent of the other Parties, and any such assignment without such prior written consent shall be null and void. 

6.5 Notices. All notices and communications hereunder shall be deemed to have been duly given and made if in writing and if served by
personal delivery upon the party for whom it is intended, or if delivered by registered or certified mail, return receipt requested, or if sent by telecopier or email in each case, to the Person at the address set forth below, or such other address
as may be designated in writing hereafter, in the same manner, by such Person: 
  

					
		
	 (a)
		 if to the Company, to:

		
			 TTM Technologies, Inc.

			 1665 Scenic Avenue, Suite 250

			 Costa Mesa, California 92626

			 Attention:
		Thomas T. Edman
			 Facsimile:
		(714) 784-3712
			 Email:
		tom.edman@ttmtech.com

  
 14 

					
		
			 with a copy (which shall not constitute notice) to:

		
			 Greenberg Traurig, LLP

			 2375 E. Camelback Road, Suite 700

			 Phoenix, Arizona 85016

			 Attention:
		Bruce E. Macdonough
					Brian H. Blaney
			 Facsimile:
		(602) 445-8100
			 Email:
		macdonoughb@gtlaw.com
					 blaneyb@gtlaw.com

		
	 (b)
		 if to any of the HM Funds, to:

		
			 Kainos Capital LLC

			 2100 McKinney Avenue, Suite 1600

			 Dallas, Texas 75201

			 Attention:
		David W. Knickel
			 Facsimile:
		(214) 720-7888
			 Email:
		dknickel@kainoscapital.com
		
			 with a copy (which shall not constitute notice) to:

		
			 Vinson & Elkins LLP

			 3700 Trammell Crow Center

			 2001 Ross Avenue

			 Dallas, Texas 75201

			 Attention:
		Robert L. Kimball
			 Facsimile:
		(214) 999-7860
			 Facsimile:
		(214) 999-7860
			 Email:
		rkimball@velaw.com
		
	 (c)
		 if to any of the BD Funds, to:

		
			 c/o Black Diamond Capital Management, L.L.C.

			 One Sound Shore Drive, Suite 200

			 Greenwich, Connecticut 06830

			 Attention:
		Legal Department
		
			 with a copy (which shall not constitute notice) to:

		
			 Latham & Watkins, LLP

			 885 Third Avenue

			 New York, New York 10022-4834

			 Attention:
		Stephen B. Amdur
			 Facsimile:
		(212) 751-4864
			 Email:
		stephen.amdur@lw.com

 The failure to provide notice in accordance with the required timing, if any, set forth herein shall affect the rights of the
Party providing such notice only to the extent that such delay actually prejudices the rights of the Party receiving such notice. 
 6.6
Headings. The headings in this Agreement are for convenience of reference only and will not control or affect the meaning or construction of any provisions hereof. 

6.7 Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision
shall not affect the validity or enforceability of the other 

  
 15 

 
provisions hereof. If any provision of this Agreement, or the application thereof to any Person or any circumstance, is invalid or unenforceable, (a) a suitable and equitable provision shall
be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other
Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction. 

6.8 Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile and other electronic
transmission), each of which will be an original with the same effect as if the signatures thereto and hereto were upon the same instrument. 

6.9 Entire Agreement. This Agreement, together with the agreements referred to herein, is intended by the Parties to be a complete and
exclusive statement of the agreement and understanding of the Parties hereto in respect of the subject matter contained herein and the registration rights granted by the Company with respect to the Registrable Securities. This Agreement supersedes
all prior agreements and undertakings among the Parties with respect to such registration rights, including that certain Registration Rights Agreement Memorandum of Understanding dated as of September 21, 2014 (which agreement is hereby
terminated). 
 6.10 Governing Law; Consent to Jurisdiction; Waiver of Trial by Jury. 

(a) THIS AGREEMENT, THE LEGAL RELATIONSHIP BETWEEN THE PARTIES AND THE ADJUDICATION AND THE ENFORCEMENT HEREOF AND THEREOF, SHALL BE GOVERNED
BY AND INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL, SUBSTANTIVE AND PROCEDURAL LAWS OF THE STATE OF DELAWARE APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED WHOLLY WITHIN THAT JURISDICTION, WITHOUT GIVING EFFECT TO THE CONFLICTS OF
LAW RULES AND PRINCIPLES THEREOF. 
 (b) Each Party to this Agreement, by its execution hereof, hereby: 

(i) irrevocably and unconditionally submits to the exclusive jurisdiction in the Court of Chancery of the State of Delaware or any court of
the United States located in the State of Delaware, for the purpose of any and all actions, suits or proceedings arising in whole or in part out of, related to, based upon or in connection with this Agreement or the subject matter hereof; 

(ii) waives to the extent not prohibited by applicable law, and agrees not to assert, by way of motion, as a defense or otherwise, in any
such action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should be
dismissed on grounds of forum non conveniens, should be transferred to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the
above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by such court; and 
 (iii) agrees not to
commence any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action to any court other than one of the above-named courts
whether on the grounds of forum non conveniens or otherwise. 
 (c) EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES
ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION UNDER THIS SECTION 6.10. THE PARTIES HERETO AGREE THAT ANY OR ALL OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY, AND BARGAINED-FOR
AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE TRIAL BY JURY AND THAT 

  
 16 

 
ANY COURT ACTION OR PROCEEDING WHATSOEVER BETWEEN THEM THAT IS PERMITTED UNDER THIS SECTION 6.10 SHALL INSTEAD BE TRIED IN A DELAWARE COURT BY A JUDGE SITTING WITHOUT A JURY. 

6.11 Specific Performance; Injunctive Relief. The Parties hereby acknowledge and agree that the failure of any Party to perform its
agreements and covenants hereunder, including its failure to take all actions as are necessary on its part to the consummation of the transactions contemplated hereby, will cause irreparable injury to the other Parties, for which damages, even if
available, will not be an adequate remedy. Accordingly, each Party hereby consents to the issuance of injunctive relief by any court of competent jurisdiction to compel performance of such Party’s obligations, to prevent breaches of this
Agreement by such Party and to the granting by any court of the remedy of specific performance of such Party’s obligations hereunder, without bond or other security being required, in addition to any other remedy to which any Party is entitled
at law or in equity. Each Party irrevocably waives any defenses based on adequacy of any other remedy, whether at law or in equity, that might be asserted as a bar to the remedy of specific performance of any of the terms or provisions hereof or
injunctive relief in any action brought therefor by any Party. 
 6.12 Interpretation. 

(a) The words “hereof,” “herein,” and “herewith” and words of similar import shall, unless otherwise stated, be
construed to refer to this Agreement as a whole and not to any particular provision of this Agreement, and article, section, paragraph, exhibit, and schedule references are to the articles, sections, paragraphs, exhibits, and schedules of this
Agreement unless otherwise specified. Whenever the words “include,” “includes,” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” All terms
defined in this Agreement shall have the defined meanings contained herein when used in any certificate or other document made or delivered pursuant hereto unless otherwise defined therein. The definitions contained in this Agreement are applicable
to the singular as well as the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such terms. In this Agreement, all references to “$” are to United States dollars. Any agreement, instrument,
or statute defined or referred to herein or in any agreement or instrument that is referred to herein means such agreement, instrument, or statute as from time to time, amended, qualified, or supplemented, including (in the case of agreements and
instruments) by waiver or consent and (in the case of statutes) by succession of comparable successor statutes and all attachments thereto and instruments incorporated therein. References to a Person are also to its permitted successors and assigns.

 (b) The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of
intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this
Agreement. 
 [Signature pages follow] 

  
 17 

 IN WITNESS WHEREOF, each of the undersigned has executed this Agreement or caused this Agreement
to be duly executed on its behalf as of the date first written above. 
  

			
	TTM TECHNOLOGIES, INC.
		
	By:	 	 /s/ Thomas T. Edman

	Name:	 	Thomas T. Edman
	Title:	 	President and Chief Executive Officer

  
 [Signature Page to
Registration Rights Agreement] 

 
			
	HM FUNDS:
	
	HICKS, MUSE, TATE & FURST EQUITY FUND III, L.P.
		
	By:	 	 HM3/GP Partners, L.P.,
 its general
partner

		
	By:	 	 Hicks, Muse GP Partners III, L.P.,
 its
general partner

		
	By:	 	 Hicks, Muse Fund III Incorporated,
 its
general partner

		
	By:	 	 /s/ David W. Knickel

	Name:	 	David W. Knickel
	Title:	 	Vice President
	
	HMTF EQUITY FUND IV (1999), L.P.
		
	By:	 	 HM4/GP (1999) Partners, L.P.,
 its general
partner

		
	By:	 	 Hicks, Muse GP (1999) Partners IV, L.P.,
 its
general partner

		
	By:	 	 Hicks, Muse (1999) Partners IV, LLC,
 its
general partner

		
	By:	 	 /s/ David W. Knickel

	Name:	 	David W. Knickel
	Title:	 	Vice President
	
	HM3 COINVESTORS, L.P.
		
	By:	 	 Hicks, Muse GP Partners III, L.P.,
 its
general partner

		
	By:	 	 Hicks, Muse Fund III Incorporated,
 its
general partner

		
	By:	 	 /s/ David W. Knickel

	Name:	 	David W. Knickel
	Title:	 	Vice President

  
 [Signature Page to
Registration Rights Agreement] 

 
			
	HMTF PRIVATE EQUITY FUND IV (1999), L.P.
		
	By:		 HM4/GP (1999) Partners, L.P.,
 its general
partner

		
	By:		 Hicks, Muse GP (1999) Partners IV, L.P.,
 its
general partner

		
	By:		Hicks, Muse (1999) Partners IV, LLC, its general partner
		
	By:		 /s/ David W. Knickel

	Name:		David W. Knickel
	Title:		Vice President
	
	HICKS, MUSE PG-IV (1999) C.V.
		
	By:		 HM Equity Fund IV/GP Partners (1999), C.V.,

its general partner

		
	By:		 HM GP Partners IV Cayman, L.P.,
 its general
partner

		
	By:		 HM Legacy LLC,
 its general
partner

		
	By:		 /s/ David W. Knickel

	Name:		David W. Knickel
	Title:		Vice President
	
	HM 4-EQ (1999) COINVESTORS, L.P.
		
	By:		 Hicks, Muse GP (1999) Partners IV, L.P.,
 its
general partner

		
	By:		 Hicks, Muse (1999) Fund IV, LLC,
 its general
partner

		
	By:		 /s/ David W. Knickel

	Name:		David W. Knickel
	Title:		Vice President

  
 [Signature Page to
Registration Rights Agreement] 

			
	HM 4-P (1999) COINVESTORS, L.P.
		
	By:		 Hicks, Muse GP (1999) Partners IV, L.P.,
 its
general partner

		
	By:		Hicks, Muse (1999) Fund IV, LLC,
			its general partner
		
	By:		 /s/ David W. Knickel

	Name:		David W. Knickel
	Title:		Vice President

  
 [Signature Page to
Registration Rights Agreement] 

 
			
	BD FUNDS:
	
	GSC RECOVERY II, L.P.
		
	By:		 GSC Recovery II GP, L.P.,
 its general
partner

		
	By:		 GSC RII, LLC,
 its general
partner

		
	By:		 GSC ACQUISITION HOLDINGS, L.L.C.,
 its
managing member

		
	By:		 GSC MANAGER, LLC,
 its manager

		
	By:		 BLACK DIAMOND CAPITAL MANAGEMENT, L.L.C.,

its member

		
	By:		 /s/ Stephen H. Deckoff

	Name:		Stephen H. Deckoff
	Title:		Managing Principal
	
	GSC RECOVERY IIA, L.P.
		
	By:		 GSC Recovery IIA GP, L.P.,
 its general
partner

		
	By:		 GSC RIIA, LLC,
 its general
partner

		
	By:		 GSC ACQUISITION HOLDINGS, L.L.C.,
 its
collateral manager

		
	By:		 GSC MANAGER, LLC,
 its manager

		
	By:		 BLACK DIAMOND CAPITAL MANAGEMENT, L.L.C.,

its member

		
	By:		 /s/ Stephen H. Deckoff

	Name:		Stephen H. Deckoff
	Title:		Managing Principal

  
 [Signature Page to
Registration Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]